ata-dtc-risk-stratification

name

ata-dtc-risk-stratification

description

Assigns ATA initial risk of recurrence (Low / Intermediate / High) to a patient with differentiated thyroid cancer (DTC) after surgery, using the ATA 2009 Modified Risk Stratification System. Use when a clinician asks "what is the ATA risk for this DTC patient", "is this low or high risk thyroid cancer", "how do I risk-stratify this thyroid cancer after surgery", "ATA risk tier for DTC", "does this patient need RAI", "what follow-up does this thyroid cancer patient need", or any post-surgical risk classification question for PTC or FTC. Source: 2015 ATA Guidelines, Haugen et al., Thyroid 2016;26(1).

ATA DTC Initial Risk Stratification Tool

Source: 2015 ATA Management Guidelines — ATA Modified 2009 Initial Risk Stratification System (Table 11).
Haugen et al. Thyroid 2016;26(1). DOI: 10.1089/thy.2015.0020

---

PURPOSE

The ATA risk tier (Low / Intermediate / High) is assigned at the time of initial surgical pathology and governs:

1. Whether RAI remnant ablation is indicated
2. Intensity of initial TSH suppression
3. Frequency and modality of follow-up
4. When and how to reclassify risk dynamically (see Dynamic Risk Stratification skill)

---

STEP 1 — Collect Pathologic and Clinical Data

Before assigning tier, confirm:

• Histologic subtype (classic PTC, follicular variant PTC, FTC, Hürthle cell, tall cell, columnar, hobnail, etc.)
• Tumor size (largest focus in cm)
• Unifocal vs. multifocal
• Completeness of resection (R0, R1, R2)
• Extrathyroidal extension: none / microscopic (pT3a ETE) / gross (pT4)
• Lymph node status: clinical N0 / pN0 / pN1 (number, size of largest node, extranodal extension)
• Vascular invasion: none / minimal (≤3 foci) / extensive (≥4 foci)
• Distant metastases: none / suspected / confirmed
• BRAF mutation status (for PTMC with multifocality and ETE)
• Post-surgical serum Tg (while hypothyroid or after rhTSH)

---

STEP 2 — Assign ATA Risk Tier

✅ ATA LOW Risk

All of the following must apply:

• Complete resection of macroscopic disease
• No local invasion (no microscopic or gross ETE)
• No regional or distant metastases
• No aggressive histologic subtype (tall cell, hobnail, columnar, diffuse sclerosing, solid/trabecular)
• No vascular invasion

AND meets one of these histologic profiles:

Profile	Details
Intrathyroidal PTC	Clinical N0, or pN1 with ≤5 lymph node micrometastases, all <0.2 cm
Intrathyroidal encapsulated follicular-variant PTC (FV-PTC)	Completely encapsulated
Intrathyroidal well-differentiated FTC	Capsular invasion only, OR minimal vascular invasion (≤3 foci)
Intrathyroidal PTMC	Unifocal OR multifocal

Estimated recurrence risk: ~1–2% for intrathyroidal PTC; <5% overall

---

⚠️ ATA INTERMEDIATE Risk

Any one of the following:

Feature	Notes
Microscopic extrathyroidal extension (pT3a)	Minimal/microscopic ETE into perithyroidal soft tissue
RAI-avid disease in the neck on first post-treatment whole body scan	Beyond thyroid bed
Aggressive histology	Tall cell, columnar, hobnail, diffuse sclerosing, solid/trabecular variants
PTC with vascular invasion	Any vascular invasion in PTC
Clinical N1	LN involvement identified clinically or on imaging
pN1 — node-positive with >5 nodes involved, all <3 cm	Metastatic nodes but none ≥3 cm
Multifocal PTMC with ETE AND BRAF mutation	Both features must be present

Estimated recurrence risk: ~3–8% (lower end) to 8–25% depending on features

---

🔴 ATA HIGH Risk

Any one of the following:

Feature	Notes
Gross (macroscopic) extrathyroidal extension (pT4)	Into major structures: strap muscles with direct invasion to adjacent structures
Incomplete surgical resection (R1/R2)	Gross residual or microscopically positive margins with known residual disease
Distant metastases (M1)	Lung, bone, or other sites
Postoperative serum Tg suggestive of distant metastases	Inappropriately elevated Tg not explained by remnant
pN1 with any single lymph node ≥3 cm	One or more metastatic nodes measuring ≥3 cm
FTC with extensive vascular invasion (≥4 foci)	Four or more foci of vascular invasion in FTC

Estimated recurrence risk: >50%

---

STEP 3 — Map Risk Tier to Initial Management Decisions

ATA Risk	RAI	TSH Suppression Goal	Initial Follow-up
Low	Not routinely recommended	TSH low-normal (0.5–2.0 mU/L)	Neck US at 6–12 months; Tg measurement
Intermediate	Consider (see RAI Decision Skill)	TSH slightly below normal (0.1–0.5 mU/L)	Neck US at 6–12 months; stimulated Tg if remnant ablation done
High	Routinely recommended (see RAI Decision Skill)	TSH <0.1 mU/L (aggressive suppression)	Imaging at 6–12 months; Tg/anti-Tg; further staging as needed

---

STEP 4 — Document for Dynamic Risk Reclassification

Record the initial ATA tier as a baseline. After 6–24 months:

• Reclassify using response-to-therapy categories (Excellent / Biochemical Incomplete / Structural Incomplete / Indeterminate)
• The initial tier informs prior probability; the response category drives ongoing management
• → Use the ATA Dynamic Risk Stratification skill for reclassification

---

CLINICAL GUARDRAILS

• ATA risk tier is a snapshot at surgery — it will be updated as Tg trends and imaging emerge (dynamic risk)
• Microscopic vs. gross ETE matters enormously — microscopic ETE (into perithyroidal fat) = Intermediate; gross ETE (into strap muscle or beyond) = High
• N1 staging is nuanced — the number AND size of nodes drives tier (≤5 micrometastases <0.2 cm = Low; >5 nodes all <3 cm = Intermediate; any node ≥3 cm = High)
• FTC with minimal vascular invasion (1–3 foci) is Low risk; extensive vascular invasion (≥4 foci) is High risk — count the foci
• PTMC multifocality alone is Low — needs BOTH ETE and BRAF mutation to step up to Intermediate
• Tg level at time of surgery should be documented — high postoperative Tg may indicate residual/distant disease and upgrade effective risk even if pathology criteria are intermediate
• This system applies to DTC (PTC + FTC) — medullary and anaplastic thyroid cancers are managed under entirely different frameworks